Document is current
Any future updates will be listed below
-
Authors
Mocking, Tim R. https://orcid.org/0000-0001-9170-4131
Haaksma, Lukas H. https://orcid.org/0009-0008-2179-4870
Reuvekamp, Tom https://orcid.org/0009-0001-1346-6606
Kelder, Angèle
Scholten, Willemijn J.
Ngai, Lok Lam https://orcid.org/0000-0003-0969-3766
Breems, Dimitri A.
Fischer, Thomas
Gjertsen, Bjørn T. https://orcid.org/0000-0001-9358-9704
Griškevičius, Laimonas
Juliusson, Gunnar https://orcid.org/0000-0002-7911-7265
Maertens, Johan A. https://orcid.org/0000-0003-4257-5980
Manz, Markus G. https://orcid.org/0000-0002-4676-7931
Pabst, Thomas https://orcid.org/0000-0002-6055-5257
Passweg, Jakob R.
Porkka, Kimmo
Valk, Peter J. M. https://orcid.org/0000-0002-8857-9461
Gradowska, Patrycja
Löwenberg, Bob https://orcid.org/0000-0001-8982-5217
de Leeuw, David C. https://orcid.org/0000-0003-4591-8467
Janssen, Jeroen J. W. M.
Ossenkoppele, Gert J.
van de Loosdrecht, Arjan A. https://orcid.org/0000-0001-8311-983X
Cloos, Jacqueline https://orcid.org/0000-0001-9150-8026
Bachas, Costa https://orcid.org/0000-0001-5983-6193
- License Information
-
More Information
Article History
Received: 9 June 2025
Revised: 25 July 2025
Accepted: 13 August 2025
First Online: 3 September 2025
Competing interests
: Gjertsen: BerGenBio: Consultancy; GreinDX: Consultancy; Immedica: Consultancy; InCyte: Consultancy; Mendus AB: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Otsuka: Consultancy; Pfizer: Consultancy, Research Funding; Sanofi: Consultancy; in Alden Cancer Therapy AS: Current holder of stock options in a privately-held company; KinN Therapeutics AS: Current holder of stock options in a privately-held company; Coegin: Consultancy. Griškevičius: Miltenyi Biomedicine: Membership on an entity’s Board of Directors or advisory committees. Juliusson: AbbVie: Honoraria; Jazz: Honoraria; Laboratoire Delbert: Other: Research cooperation; Novartis: Honoraria; Servier: Honoraria. Löwenberg: Servier Advisory Board; Syndax Pharmaceuticals Advisory Board; Ryvu Pharmaceuticals Consultant. de Leeuw: Takeda: Membership on an entity’s Board of Directors or advisory committees; Abbvie: Consultancy; Roche: Consultancy; Servier: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Ellipses Pharma: Research Funding. van de Loosdrecht: BMS: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Celgene: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Roche: Research Funding. Ossenkoppele: Servier: Consultancy; Abbvie: Consultancy; Roche: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Astellas: Consultancy, Honoraria; Gilead: Consultancy; Amgen: Consultancy; AGIOS: Consultancy, Honoraria; Janssen: Novartis and Bristol Myers Squibb: research funding; Incyte: speaker’s fee; AbbVie, Novartis, Pfizer, and Incyte: honoraria (all to institute); president of nonprofit Apps for Care and Science foundation which received unrestricted educational grants from AbbVie, Alexion, Amgen, Astellas, Astra Zeneca, Bristol Myers Squibb, Daiichi Sankyo, Janssen-Cilag, Novartis, Novo-Nordisk, Incyte, Sanofi Genzyme, Servier, Sobi, Jazz, and Takeda; Cloos: Navigate: Consultancy, Patents & Royalties: Royalties MRD assay; BD Biosciences: Patents & Royalties: Royalties LSC tube; Takeda: Research Funding; Novartis: Consultancy, Research Funding.
